What is Lu-177 DOTA-Octreotate treatment?
Lutetium-177 is a radioactive substance that can be added to a carrier called DOTAOctreotate. Once in your body, the Lu-177 DOTA-Octreotate attaches well to certain receptors (called somatostatin-receptor) which are almost exclusively found on neuroendocrine tumours. The radioactive Lu-177 then destroys these cancerous cells.
This treatment is known to be effective in gastroenteropancreatic (GEP) neuroendocrine tumours, such as:
- Intestinal carcinoids
- Tumours of the pancreas
- Bronchial carcinoids
This treatment can also be used for other slow growing tumours, such as:
- Carotid body tumours
- Medullary thyroid cancer
- Thymic tumours
The team looking after you at the WELLNET Unit will consist of a team of neuroendocrine tumour specialists including doctors, clinical nurse specialists and nuclear medicine physicians.